GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » 3-Year EPS without NRI Growth Rate

Ignyta (Ignyta) 3-Year EPS without NRI Growth Rate : 0.00% (As of Sep. 2017)


View and export this data going back to 2014. Start your Free Trial

What is Ignyta 3-Year EPS without NRI Growth Rate?

Ignyta's EPS without NRI for the three months ended in Sep. 2017 was $-0.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Competitive Comparison of Ignyta's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Ignyta's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ignyta's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ignyta's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Ignyta's 3-Year EPS without NRI Growth Rate falls into.



Ignyta 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Ignyta  (NAS:RXDX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Ignyta 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Ignyta's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Ignyta (Ignyta) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
N/A
Address
Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.
Executives
James L Freddo director 3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani officer: Chief Medical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim director, 10 percent owner, officer: President, CEO & Director 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko officer: Chief Financial Officer C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky officer: GM, Immuno-Oncology/SVP Sp Ops C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis officer: General Counsel and Secretary C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin 03-23-2021